Skip to main content

Mikhail A. Nikiforov

Professor of Pathology
210 Research Drive, GSRB II, Rm. 4020, Durham 27710

Selected Publications

Distinct inflammatory Th17 subsets emerge in autoimmunity and infection.

Journal Article J Exp Med · October 2, 2023 Th17 cells play a critical role in both tissue homeostasis and inflammation during clearance of infections as well as autoimmune and inflammatory disorders. Despite numerous efforts to distinguish the homeostatic and inflammatory roles of Th17 cells, the m ... Full text Link to item Cite

Compartmentalization and regulation of GTP in control of cellular phenotypes.

Journal Article Trends Mol Med · September 2022 Genetic or pharmacological inhibition of enzymes involved in GTP biosynthesis has substantial biological effects, underlining the need to better understand the function of GTP levels in regulation of cellular processes and the significance of targeting GTP ... Full text Open Access Link to item Cite

Phosphorylation of guanosine monophosphate reductase triggers a GTP-dependent switch from pro- to anti-oncogenic function of EPHA4.

Journal Article Cell Chem Biol · June 16, 2022 Signal transduction pathways post-translationally regulating nucleotide metabolism remain largely unknown. Guanosine monophosphate reductase (GMPR) is a nucleotide metabolism enzyme that decreases GTP pools by converting GMP to IMP. We observed that phosph ... Full text Open Access Link to item Cite

Regulation of local GTP availability controls RAC1 activity and cell invasion.

Journal Article Nat Commun · October 19, 2021 Physiological changes in GTP levels in live cells have never been considered a regulatory step of RAC1 activation because intracellular GTP concentration (determined by chromatography or mass spectrometry) was shown to be substantially higher than the in v ... Full text Open Access Link to item Cite

The fatty acid elongase ELOVL6 regulates bortezomib resistance in multiple myeloma

Journal Article Blood Advances · April 13, 2021 AbstractResistance to the proteasome inhibitor bortezomib (BTZ) represents a major obstacle in the treatment of multiple myeloma (MM). The contribution of lipid metabolism in the resistance of MM cells to BTZ is mostly unkn ... Full text Open Access Cite